



## Zafgen to Present at Deutsche Bank 43rd Annual Health Care Conference

May 2, 2018

BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield, Chief Executive Officer of Zafgen, Inc. will present a company overview at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:00 a.m. ET.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website ([www.zafgen.com](http://www.zafgen.com)) for 90 days following the conclusion of the live event.

### About Zafgen

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company's lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at [www.zafgen.com](http://www.zafgen.com).

### Media/Investor Relations Contacts:

Zafgen, Inc.  
Patricia Allen  
Chief Financial Officer  
617-648-9792

*Media*  
Krystle Gibbs  
Ten Bridge Communications  
[krystle@tenbridgecommunications.com](mailto:krystle@tenbridgecommunications.com)  
508-479-6358

*Investors*  
John Woolford  
Westwicke Partners  
[John.woolford@westwicke.com](mailto:John.woolford@westwicke.com)  
443-213-0506

[Primary Logo](#)

Source: Zafgen, Inc.